Short Versus Long-acting Erythropoiesis-stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients

Overview

Journal Qatar Med J

Specialty General Medicine

Date 2024 Apr 3

PMID 38567102

Authors

Amira Elsawy Soliman

Salma Magdy

Hazem Sayed Ayoub

Abdel-Hameed Ibrahim Ebid

Affiliations

Soon will be listed here.

Abstract

Background: Chronic kidney disease (CKD) often results in renal anemia, impacting the well-being of patients and causing various negative consequences. Erythropoiesis-stimulating agents (ESAs) offer promising solutions for managing anemia in CKD. This study aimed to evaluate and compare the effectiveness, safety profile, and cost-effectiveness of short-acting (Eprex) and long-acting (Aranesp) ESAs.

Method: This comparative prospective cohort cost-effectiveness study was carried out over 6 months among adult Egyptian hemodialysis patients of either gender. Participants were categorized into two groups based on the type of ESA administered: the Eprex group, receiving epoetin alfa, and the Aranesp group, receiving darbepoetin alfa. These two treatment groups' efficacy, safety, and cost were analyzed and compared.

Results: Of 127 hemodialysis patients, 60 (47.2%) received Eprex, while 67 (52.8%) were treated with Aranesp. Target hemoglobin (Hb) was achieved by 50.6% of patients in the Eprex group versus 63.4% in the Aranesp group, with a significant difference ( < 0.001). Both treatment groups exhibited a similar safety profile, while Aranesp was considered the cost-saving protocol.

Conclusion: In hemodialysis Egyptian patients, Aranesp with extended dosing intervals proved to be more effective in achieving target Hb with comparable adverse effect profiles, a substantial cost-saving strategy, and offered time-saving advantages for medical staff workload compared to Eprex.

Trial Registration: The Clinicaltrial.gov registration ID is NCT05699109 (26/01/2023).

References

Stephens J, Emerson L, Spry L, Caloyeras J, Anderson E, Reitan J . Time savings of weekly versus three-times-per-week administration of erythropoiesis stimulating agents in United States dialysis patients. Curr Med Res Opin. 2015; 32(2):313-20. DOI: 10.1185/03007995.2015.1123144. View

Kovesdy C . Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022; 12(1):7-11. PMC: 9073222. DOI: 10.1016/j.kisu.2021.11.003. View

Chen N, Xing C, Niu J, Liu B, Fu J, Zhao J . Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trail. Chronic Dis Transl Med. 2022; 8(1):59-70. PMC: 9128564. DOI: 10.1002/cdt3.13. View

Lawesson S, Swahn E, Alfredsson J . Adherence to Study Drugs: A Matter of Sex?. Circulation. 2021; 143(7):696-698. DOI: 10.1161/CIRCULATIONAHA.121.053493. View

Moreno F, Lopez Gomez J, Sanz-Guajardo D, Jofre R, Valderrabano F . Quality of life in dialysis patients. A spanish multicentre study. Spanish Cooperative Renal Patients Quality of Life Study Group. Nephrol Dial Transplant. 1996; 11 Suppl 2:125-9. DOI: 10.1093/ndt/11.supp2.125. View

Eschbach J . The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989; 35(1):134-48. DOI: 10.1038/ki.1989.18. View

Kim Y, Evangelista L, Phillips L, Pavlish C, Kopple J . The End-Stage Renal Disease Adherence Questionnaire (ESRD-AQ): testing the psychometric properties in patients receiving in-center hemodialysis. Nephrol Nurs J. 2010; 37(4):377-93. PMC: 3077091. View

Jordan J, Breckles J, Leung V, Hopkins M, Battistella M . Conversion from epoetin alfa to darbepoetin alfa: effects on patients' hemoglobin and costs to canadian dialysis centres. Can J Hosp Pharm. 2013; 65(6):443-9. PMC: 3517789. DOI: 10.4212/cjhp.v65i6.1192. View

Gutierrez O . Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease. Kidney Int Rep. 2021; 6(9):2261-2269. PMC: 8418942. DOI: 10.1016/j.ekir.2021.05.020. View

10.

Regidor D, Kopple J, Kovesdy C, Kilpatrick R, McAllister C, Aronovitz J . Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006; 17(4):1181-91. DOI: 10.1681/ASN.2005090997. View

11.

Naalweh K, Barakat M, Sweileh M, Al-Jabi S, Sweileh W, Zyoud S . Treatment adherence and perception in patients on maintenance hemodialysis: a cross - sectional study from Palestine. BMC Nephrol. 2017; 18(1):178. PMC: 5450383. DOI: 10.1186/s12882-017-0598-2. View

12.

Palmer S, Saglimbene V, Mavridis D, Salanti G, Craig J, Tonelli M . Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2014; (12):CD010590. PMC: 6885065. DOI: 10.1002/14651858.CD010590.pub2. View

13.

Rao M, Pereira B . Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. Kidney Int. 2005; 68(4):1432-8. DOI: 10.1111/j.1523-1755.2005.00554.x. View

14.

Efstratiadis G, Konstantinou D, Chytas I, Vergoulas G . Cardio-renal anemia syndrome. Hippokratia. 2008; 12(1):11-6. PMC: 2532969. View

15.

Singh A . Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro. J Am Soc Nephrol. 2009; 20(7):1436-41. DOI: 10.1681/asn.2009040444. View

16.

Al-Ali F, El-Sayed Abdelfattah M, Fawzy A, Hamdy A, Abdulla A . Erythropoietin-stimulating agents in the management of anemia of end-stage renal disease patients on regular hemodialysis: a prospective randomized comparative study from Qatar. Hemodial Int. 2014; 19(1):33-43. DOI: 10.1111/hdi.12181. View

17.

Farag Y, El-Sayed E . Global Dialysis Perspective: Egypt. Kidney360. 2022; 3(7):1263-1268. PMC: 9337895. DOI: 10.34067/KID.0007482021. View

18.

Egrie J, Browne J . Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001; 84 Suppl 1:3-10. PMC: 2363897. DOI: 10.1054/bjoc.2001.1746. View

19.

Sinha S, Bandi V, Bheemareddy B, Thakur P, Chary S, Mehta K . Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial. BMC Nephrol. 2019; 20(1):90. PMC: 6417108. DOI: 10.1186/s12882-019-1209-1. View

20.

Carrera F, Burnier M . Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations. NDT Plus. 2009; 2(Suppl_1):i9-i17. PMC: 2638549. DOI: 10.1093/ndtplus/sfn175. View